The U.S. Food and Drug Administration (FDA) has cleared Ezra Prostate AI, an artificial intelligence (AI) program designed to increase the efficiency with which radiologists analyze images of the prostate in order to diagnose prostate cancer. The program, which is expected to decrease the cost of prostate MRIs, is the first-ever prostate segmentation AI to be cleared by the FDA, Ezra announced in a press release. Despite the commonality of prostate cancer, there aren’t reliable…
You must be logged in to read/download the full post.
The post FDA Clears Ezra Prostate AI, a First for Cancer Imaging appeared first on BioNewsFeeds.